-
Mashup Score: 0Enhertu Improves Progression-Free Survival in HR+, HER2-Low/Ultralow Metastatic Breast Cancer - 4 hour(s) ago
Data from the phase 3 DESTINY-Breast06 trial were presented during the 2024 San Antonio Breast Cancer Symposium.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet
-
Mashup Score: 0Treatment Discontinuations Reduced With Jaypirca in CLL, SLL - 6 hour(s) ago
Jaypirca showed superior progression-free survival and lower discontinuation rates versus standard treatments in patients with previously treated CLL or SLL.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet-
For patients with previously treated chronic lymphocytic leukemia or small lymphocytic #lymphoma, Jaypirca improved progression-free survival with low rates of treatment discontinuation versus the investigator’s choice of treatment, as presented at #ASH24. https://t.co/mwGxY0A4to
-
-
Mashup Score: 0
Autologous stem cell transplant plus Rituxan did not improve survival outcomes in certain patients with mantle cell lymphoma compared with Rituxan alone.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet-
Patients with mantle cell #lymphoma did not show improved survival after receiving consolidative autologous hematopoietic cell transplant with Rituxan in their first complete remission with undetectable minimal residual disease, as presented at #ASH24. https://t.co/PCirE01wIe
-
-
Mashup Score: 0Prostate Cancer Questions Answered on Surgery, Side Effects and More - 11 hour(s) ago
An expert answered CURE® readers’ questions on several aspects of a prostate cancer journey, including treatment options and sexual function.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet-
Read one of the latest articles where an expert answers CURE readers’ questions about prostate cancer and treatment options. Learn more: https://t.co/Qwynp4WNSc https://t.co/NxMdKkSHd2
-
-
Mashup Score: 0
Setbacks happen often in life, but finding gratitude can come at unexpected moments with cancer.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet-
During a season of gratitude, sometimes it can be difficult to search for gratitude when setbacks arise, Martha found. However, she reminds herself that even with metastatic cancer, temporary setbacks are OK. #BCSM Read Martha's latest blog here: https://t.co/vEfPMBAvwp https://t.co/va0pAxSRHL
-
-
Mashup Score: 0
Updated data from the phase 3 DREAMM-7 trial was presented during the 2024 ASH Annual Meeting and Exposition.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet-
Patients with relapsed/refractory #MultipleMyeloma experienced significant improvements survival when treated with Blenrep with Velcade and dexamethasone versus those treated with Darzalex plus Velcade and dexamethasone, as presented at #ASH24. https://t.co/VDQV9gj1wK
-
-
Mashup Score: 0CURE - 1 day(s) ago
CURE provides access to the cancer news, latest oncology research & expert insights that serve as a guide to every stage of the cancer experience.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet-
New issue alert! The latest edition of CURE® delves into the complexities of utilizing clinical trials in cancer care. Discover Hyunji Kim's inspiring journey with antibody-drug conjugates for breast cancer treatment. Read now: https://t.co/PlKPREdImG https://t.co/fBsN3jDFwt
-
-
Mashup Score: 0
A Phase 3 trial of uproleselan failed to improve overall survival in relapsed/refractory AML, though it may benefit primary refractory patients.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet-
For patients with relapsed/refractory #AcuteMyeloidLeukemia, a phase 3 trial evaluating the efficacy of uproleselan with chemotherapy versus chemotherapy alone did not demonstrate improvement in survival, as presented at #ASH2024. #ASH24 https://t.co/0tiAZoLKlc
-
-
Mashup Score: 0Venclexta Plus Mavenclad Boosts Response Rates in AML, MDS - 1 day(s) ago
The Venclexta-based regimen improved complete response rates in patients with acute myeloid leukemia and myelodysplastic syndromes.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet-
Certain patients newly diagnosed with #AML or have high-risk #MDS showed improved responses to treatment with Mavenclad plus Venclexta, according to a presentation at #ASH24. #bloodcancer #MedTwitter Read more: https://t.co/wYqOGysWjk
-
-
Mashup Score: 0
In patients with certain B-cell blood cancers, heart-related side effects may occur less after receiving second-generation BTK inhibitors.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet-
When patients with certain B-cell #BloodCancers received second-generation Bruton tyrosine kinase (BTK) inhibitors, side effects associated with the heart were linked with a significantly lower occurrence, as presented at the #ASH2024. #ASH24 https://t.co/FYQHpav7KC
-
At #SABCS24, Enhertu was shown to improve progression-free survival in patients with HR-positive, HER2-low or ultralow metastatic #breastcancer compared with physician's choice treatment in a phase 3 trial. #bcsm #MedTwitter Read more: https://t.co/4KB9duJDPy